BRD2 and polycystic ovary syndrome: For LH/FSH, no significant differences were observed through subgroups of type of flavonoid (p=0.3), dose (p=0.08), duration of administration (p=0.17), and PCOS induction drug (p=0.4) (Table 5 and Figure S9).